SL Pharm: TVM Capital and Chongqing Pharma Form China InLicensing Fund

TVM Capital Life Science of Germany closed the first tranche of its China BioPharma Capital I fund at $50 Million with Chongqing Lummy Pharma the strategic partner and apparently the only investor. The Capital I fund will seek to inlicense China rights to ...